SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Allogene Therapeutics, Inc. (ALLO) News

Follow Allogene Therapeutics, Inc. (ALLO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ALLO Asset equity Sector Markets 90 days 11 Last 0.7425 Updated Nov 05, 2026, 09:57 PM UTC Open live news feed Open ALLO chart & news
M Allogene Therapeutics Q3 2026 Earnings Call Begins Allogene Therapeutics’ quarterly earnings call has begun. EQUITY | Nov 05, 2026, 09:57 PM UTC L Allogene Therapeutics 3Q Loss/Shr 15c >ALLO Allogene Therapeutics 3Q Loss/Shr 15c >ALLO EQUITY | Nov 05, 2026, 09:09 PM UTC M Allogene Therapeutics Announces November Investor Events on Q3 Results and ALLO-329 Data The company says its November investor events will highlight Q3 results and initial ALLO-329 autoimmune clinical data. EQUITY | Oct 29, 2026, 12:31 PM UTC M Allogene Therapeutics Q3'26 Earnings Preview Allogene Therapeutics is scheduled to report Q3'26 results on October 29; the release time is not specified. EQUITY | Oct 28, 2026, 11:04 AM UTC L ALLO advances cema-cel and ALLO-329 with strong interim data ALLO says its cema-cel and ALLO-329 programs are advancing with strong interim data and broader MRD testing adoption. Commercial launch planning is underway, and its financial runway extends into 2029. EQUITY | Sep 09, 2026, 01:52 PM UTC L ALLO: Cema-cel demonstrates strong MRD clearance, with major clinical and commercial milestones ahead Significant progress was reported across lead programs, with cema-cel showing strong MRD clearance and commercial planning underway. MRD testing adoption is rising, and the company is positioned ahead of competitors in t EQUITY | Sep 09, 2026, 01:26 PM UTC L Allogene Therapeutics names Zachary Roberts CEO; Geoffrey Parker retires Nov 6, 2026 Allogene Therapeutics elevated Chief Medical Officer and President Zachary Roberts to CEO, succeeding David Chang. CFO Geoffrey Parker will retire Nov. 6, 2026 but remain to lead finance during an external search for a r EQUITY | Sep 07, 2026, 11:22 AM UTC L Allogene CFO Geoffrey Parker to retire effective Nov. 6 Allogene Therapeutics said CFO Geoffrey Parker will retire effective Nov. 6, adding to leadership changes after Zachary Roberts was elevated to chief executive. EQUITY | Sep 02, 2026, 12:57 PM UTC L Allogene CFO Geoffrey Parker to retire Nov. 6, 2026 Allogene said Executive Vice President and Chief Financial Officer Geoffrey Parker will retire from the company effective Nov. 6, 2026. REGULATION | Sep 02, 2026, 12:44 PM UTC L Allogene Therapeutics CFO to continue through Nov 6 retirement Allogene Therapeutics will continue to serve its CFO through his retirement date of Nov 6. EQUITY | Sep 02, 2026, 12:31 PM UTC L Allogene Therapeutics announces CFO Geoffrey Parker retirement Allogene Therapeutics announced the retirement of its Chief Financial Officer, Geoffrey Parker. EQUITY | Sep 02, 2026, 12:30 PM UTC M Allo Files $500M Mixed Shelf Offering Allo files $500,000,000 mixed shelf offering EQUITY | Aug 12, 2026, 08:24 PM UTC L Allogene Therapeutics Reports Q2 2026 Results Allogene Therapeutics reports second quarter 2026 financial results and business update EARNINGS | Aug 12, 2026, 08:05 PM UTC L ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update ALLO - Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update EARNINGS | Aug 04, 2026, 12:30 PM UTC H Allogene: No Serious Adverse Events For Cema-Cel Allogene reports no serious adverse events for cema-cel EQUITY | Jul 29, 2026, 12:36 PM UTC L ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) ALLO Allogene Therapeutics receives FDA regenerative Medicine advanced therapy (rmat) designation for cemacabtagene ansegedleucel (cema-cel) as first-line consolidation therapy for large B-cell lymphoma REGULATION | Jul 29, 2026, 12:30 PM UTC L ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car ALLO Journal of Clinical Oncology Publication of Phase 1 Results of ALLO 316 Highlighting First Durable Remissions Following Allogeneic Car T for Treatment of Metastatic Solid Tumors EQUITY | Jul 15, 2026, 01:30 PM UTC